You may be eligible if you: Have a BMI over 30, or over 27 with weight-related health concerns Struggle with appetite control or weight loss despite lifestyle changes Are not currently pregnant or breastfeeding Have not had bariatric surgery within the last 18 months Do not have a history of contraindicated conditions such as pancreatitis, medullary thyroid cancer, pancreatitis, or MEN syndrome, or certain kinds of endocrine cancers Are committed to monthly check-ins and physician-guided care *During your consultation, a medical provider will review your health history, lab work, and goals to determine your eligibility for GLP-1 treatment for weight loss
Vasodilation is mediated via agonism of endothelial 5-HT receptors in the blood vessels by serotonin, causing an increased release of endothelial-derived relaxing factor leading to the release of nitric oxide, a potent vasodilator
Several studies have reported decreased expression of NMDA (73, 76, 77) and AMPA receptor subunits (77, 78) in PFC of depressed individuals
Elevated intracellular GSH (or precursors like NAC) in autoimmune conditions has been shown to downregulate the activity of NF-B which mediates pro-inflammatory gene transcription (Limongi et al., 2019)
It's been specifically developed for professional athletes
